Clinical Trials

CNS

Ependymoma, Medulloblastoma, Central Nervous System Neoplasms

NCT05472623 2025-09-15

Neo-Kan

Resectable Non-Small Cell Lung Cancer

NCT06410534 2025-09-11

A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

Colorectal Neoplasms

NCT05717140 2025-08-07

Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung

Melanoma

NCT03879811 2025-05-15

Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer

Colorectal Neoplasms

NCT05743270 2025-03-11

Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

Squamous Cell Carcinoma of Head and Neck

NCT04781855 2025-02-28

Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

NCT03167177 2025-02-21

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

Melanoma

NCT03169738 2025-02-21

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Carcinoma, Non-Small-Cell Lung

NCT03169777 2025-02-21

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

Colorectal Neoplasms

NCT05898828 2024-08-05

Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer

Esophageal Neoplasms, Neoplasms

NCT06357858 2024-07-03

ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT05153304 2024-06-10

Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers

Gastrointestinal Neoplasms, Neoplasms

NCT06400264 2024-05-06

Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT05472506 2024-03-15

Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04151563 2023-12-19

CheckMate 79X

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT04361058 2023-12-05

Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide

MyeloidOther hematologic neoplasm

GATA2 Deficiency, Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05039736 2023-05-12

A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05504642 2023-04-18

CERAD-IMMUNE

Gynecologic

Uterine Cervical Neoplasms, Lymphatic Metastasis

NCT04965714 2023-02-16

Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer

Phase EARLY_PHASE1 Withdrawn

Resectable Hepatocellular Carcinoma

NCT04891718 2022-07-08

CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia

DermatologicHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lymphoma, Melanoma, Sarcoma

NCT05022394 2022-05-27

Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03770299 2022-03-24

CheckMate 9TN

Carcinoma, Non-Small-Cell Lung

NCT04044209 2022-01-20

A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04758949 2022-01-11

FL-101 in Surgically Resectable Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

NCT04430985 2021-10-27

IMMUNOX

Colorectal Neoplasms

NCT05001360 2021-10-27

Study of FMT Combined With Nivolumab in Gastric Cancer

Phase NA Withdrawn

Adenocarcinoma Of Esophagus

NCT04955262 2021-07-08

A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab

Melanoma

NCT04060407 2021-06-01

CINDI

Melanoma

NCT03390738 2021-05-03

Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy

Nasopharyngeal Carcinoma

NCT04042506 2021-04-12

SBRT as a Vaccination for Metastatic Melanoma

Melanoma

NCT03576963 2021-04-05

Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer

Colorectal Neoplasms

NCT03920631 2021-03-23

MicroBLITZ

Lymphoid

Lymphoma, B-Cell

NCT04495010 2021-03-19

CheckMate 7UA

Melanoma

NCT03758729 2021-02-16

Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.

Melanoma

NCT04230330 2020-11-05

Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma

Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT04315155 2020-10-28

BENEFIT

Tumor-Agnostic

Adenocarcinoma

NCT04128020 2020-10-12

Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03014804 2020-07-24

Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma

CNSSarcoma

Glioblastoma, Oligodendroglioma, Gliosarcoma

NCT03704077 2020-05-19

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Stomach Neoplasms

NCT03927248 2020-05-07

PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer

Genitourinary

Carcinoma, Renal Cell

NCT04125719 2020-02-11

PPD1

Melanoma

NCT04007588 2020-02-05

A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

Melanoma

NCT04044651 2020-01-09

Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection

Phase 2/3 Withdrawn

Hepatitis B, Carcinoma, Hepatocellular

NCT03342352 2019-12-20

Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)

Phase 3 Withdrawn

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03767439 2019-12-18

Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome

Basal Cell Nevus Syndrome

NCT02466568 2019-09-09

Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung

Adenocarcinoma of Lung, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis

NCT03575234 2019-08-28

Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer

Squamous Cell Carcinoma of Head and Neck

NCT03726281 2019-08-21

Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors

Neoplasms, Germ Cell and Embryonal

NCT03652233 2019-06-20

Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck